Harbor Capital Advisors Inc. Purchases 16,466 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Capital Advisors Inc. raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 145,379 shares of the medical equipment provider’s stock after purchasing an additional 16,466 shares during the period. Harbor Capital Advisors Inc.’s holdings in Lantheus were worth $13,006,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Signaturefd LLC boosted its holdings in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC purchased a new position in Lantheus during the 2nd quarter valued at $47,000. UMB Bank n.a. raised its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus in the 3rd quarter worth about $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LNTH shares. JMP Securities reduced their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Truist Financial reissued a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Up 2.4 %

NASDAQ:LNTH traded up $2.21 during trading hours on Friday, reaching $96.21. 205,932 shares of the company traded hands, compared to its average volume of 760,219. The business’s 50-day moving average price is $90.63 and its two-hundred day moving average price is $99.30. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market capitalization of $6.69 billion, a P/E ratio of 16.01 and a beta of 0.46.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.